A Markov modelled pharmacoeconomic analysis of bimatoprost 0.03% in the treatment of glaucoma as an alternative to filtration surgery in Italy

Current Medical Research and Opinion

Volumn 21, Issue 11, 2005, Pages 1837-1843

  Christensen, Torsten Lundgaard ^a   Poulsen, Peter Bo ^a   Holmstrom, Stefan ^b   Walt, John G ^c   Vetrugno, Michele ^d  

^a MUUSMANN Research and Consulting   (Denmark)

^b Allergan France SAS   (France)

^c Global Health Outcomes   (United States)

^d UNIVERSITY OF BARI   (Italy)

Author keywords

Bimatoprost; Costs; Glaucoma; IOP; Italy; Trabeculectomy

Indexed keywords

BIMATOPROST; EYE DROPS; TIMOLOL;

ADD ON THERAPY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG COST; DRUG EFFICACY; FILTERING OPERATION; GLAUCOMA; GLAUCOMA SURGERY; HEALTH CARE COST; HUMAN; INTERMETHOD COMPARISON; INTRAOCULAR PRESSURE; ITALY; MAJOR CLINICAL STUDY; MONOTHERAPY; OPHTHALMOLOGY; PROBABILITY; SIDE EFFECT; STATISTICAL MODEL; TREATMENT OUTCOME;

AGED; AMIDES; COST-BENEFIT ANALYSIS; FILTERING SURGERY; GLAUCOMA; HEALTH CARE COSTS; HUMANS; INTRAOCULAR PRESSURE; ITALY; LIPIDS; MARKOV CHAINS; OPHTHALMIC SOLUTIONS;

EID: 27944475069     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X65592     Document Type: Conference Paper

References (25)

1. Weinreb RN. A rationale for lowering intraocular pressure in glaucoma. Surv Ophthalmol 2001;45(Suppl 4):S335-S336
2. AGIS Investigators. The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000;130:490-1
3. European Glaucoma Society. Terminology and guidelines for glaucoma, 2nd ed. Savona, Italy: Editrice Dogma; 2003
4. Rouland JF, Hågå A, Bengtsson S, et al. What triggers change of therapy? In: Jönsson B, Krieglstein G, editors. Primary open-angle glaucoma. Differences in international treatment patterns and costs. Oxford: Isis Medical Media Ltd.; 1999. p. 162-8
5. Marchetti A, Magar R, An P, et al. Clinical and economic impact of new trends in glaucoma treatment. Med Gen Med 2001;3:6
6. Strutton DR, Walt JG. Trends in glaucoma surgery before and after the introduction of new topical glaucoma pharmacotherapies. J Glaucoma 2004;13:221-6
7. Whittaker KW, Gillow JT, Cunliffe IA. Is the role of trabeculectomy in glaucoma management changing? Eye 2001;15:49-452
8. Bateman DN, Clark R, Azuara-Blanco A, et al. The effects of new topical treatments on management of glaucoma in Scotland: an examination of ophthalmological health care. Br J Ophthalmol 2002;86:551-4
9. Hurst J, Siciliani L. Tackling excessive waiting times for elective surgery: a comparison of policies in twelve OECD countries [OECD Health Working Papers 6]. Paris: OECD; 2003
10. Vetrugno M, Sborgia C, Balestrazzi E, et al. Efficacy and safety of bimatoprost in patients with uncontrolled glaucoma as alternative to filtration surgery. Eur J Ophthalmol 2005;15:477-81
11. Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001;108:1943-53
12. Buxton MJ, Drummond MF, Van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997;6:217-27
13. Keeler K. Decision trees and Markov models in cost-effectiveness research [Chapter 9] In: Sloan FA, editor. Valuing health care. Cambridge University Press; 1995
14. Kobelt G, Jonsson L, Gerdtham U, Krieglstein GK. Direct costs of glaucoma management following initiation of medical therapy. A simulation model based on an observational study of glaucoma treatment in Germany. Graefe's Arch Clin Exp Ophthalmol 1998;236:811-21
15. Kobelt G, Jonsson L. Modeling cost of treatment with new topical treatments for glaucoma. Results from France and the United Kingdom. Int J Technol Assess Health Care 1999;15:207-19
16. Garattini L, Grilli R, Scopelliti D, Mantovani L. A proposal for Italian guidelines in pharmacoeconomics. Pharmacoeconomics 1995;7:1-6
17. Duffield C. The Delphi technique: a comparison of results obtained using two expert panels. Int J Nurs Stud 1993;30:227-37
18. Ziglio E. The Delphi method and its contribution to decision making. In: Adler M, Ziglio E, editors. Gazing into the oracle: the Delphi method and its application to social policy and public health. London: Jessica Kingsley Publishers; 1996. p. 3-33
19. Sonnenberg FA, Beck JR. Markov models in medical decision making. A practical guide. Med Decis Mak 1993;13:322-38
20. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998;13:397-409
21. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. Am J Ophthalmol 1995;120:718-31
22. Tuil E, Hommer AB, Poulsen PB, et al. The cost-effectiveness of bimatoprost 0.03% in the treatment of glaucoma in adult patients - a European perspective. Int J Clin Pract 2005;59:1011-6
23. Janz NK, Wren PA, Lichter PR, et al. The Collaborative Initial Glaucoma Treatment Study. Interim quality of life findings after initial medical or surgical treatment of glaucoma. Ophthalmology 2001;108:1954-65
24. Garrison L, Towse A. The drug budget silo mentality in Europe: an overview. Value Health 2003;6(S1):S1-S9
25. Drummond M, Jönsson B. Moving beyond the drug budget silo mentality in Europe. Value Health 2003;6(S1):S74-S77